Cargando…

Update Overview of the Role of Angiopoietins in Lung Cancer

Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsakogiannis, Dimitris, Nikolakopoulou, Asimina, Zagouri, Flora, Stratakos, Grigorios, Syrigos, Konstantinos, Zografos, Eleni, Koulouris, Nikolaos, Bletsa, Garyfalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625006/
https://www.ncbi.nlm.nih.gov/pubmed/34833409
http://dx.doi.org/10.3390/medicina57111191
_version_ 1784606312403828736
author Tsakogiannis, Dimitris
Nikolakopoulou, Asimina
Zagouri, Flora
Stratakos, Grigorios
Syrigos, Konstantinos
Zografos, Eleni
Koulouris, Nikolaos
Bletsa, Garyfalia
author_facet Tsakogiannis, Dimitris
Nikolakopoulou, Asimina
Zagouri, Flora
Stratakos, Grigorios
Syrigos, Konstantinos
Zografos, Eleni
Koulouris, Nikolaos
Bletsa, Garyfalia
author_sort Tsakogiannis, Dimitris
collection PubMed
description Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascular integrity. In particular, Angiopoietin-1 activates the endothelial cell (EC)-specific receptor tyrosine kinase, Tie2, which is essential for preserving endothelial quiescence. On the other hand, Angiopoietin-2 acts as an inhibitor of the Angiopoietin-1/Tie2 signaling pathways, thus facilitating the destabilization of quiescent endothelium in cases of inflammation and cancer. Clinical studies have proven that high levels of Angiopoietin-2 indicate the development of non-small-cell lung carcinomas (NSCLC), while high levels of Angiopoietin-2 are strongly related to tumor angiogenesis, lymphangiogenesis, metastasis, and poor prognosis. Interestingly, the association of Angiopoietin-2 levels with the type of surgical approach makes Angiopoietin-2 a valuable factor in selecting the most suitable therapeutic strategy for lung cancer patients. The role of the Angiopoietin-1 and Angiopoietin-4 levels in NSCLC development requires further investigation. The present review focuses on the clinical impact of the Angiopoietin-1, Angiopoietin-2, and Angiopoietin-4 levels in patients diagnosed with NSCLC, emphasizing the interaction between them, and how they affect the development, progression, and metastasis of lung disease. Finally, it estimates the role of angiopoietins levels in the effective therapy of lung cancer patients.
format Online
Article
Text
id pubmed-8625006
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86250062021-11-27 Update Overview of the Role of Angiopoietins in Lung Cancer Tsakogiannis, Dimitris Nikolakopoulou, Asimina Zagouri, Flora Stratakos, Grigorios Syrigos, Konstantinos Zografos, Eleni Koulouris, Nikolaos Bletsa, Garyfalia Medicina (Kaunas) Review Angiogenesis is a biological process that involves the formation of new blood vessels from the existing vasculature, and it plays a fundamental role in the development and progression of several types of cancer, including lung cancer. The angiopoietin/Tie2 ligand/receptor system orchestrates vascular integrity. In particular, Angiopoietin-1 activates the endothelial cell (EC)-specific receptor tyrosine kinase, Tie2, which is essential for preserving endothelial quiescence. On the other hand, Angiopoietin-2 acts as an inhibitor of the Angiopoietin-1/Tie2 signaling pathways, thus facilitating the destabilization of quiescent endothelium in cases of inflammation and cancer. Clinical studies have proven that high levels of Angiopoietin-2 indicate the development of non-small-cell lung carcinomas (NSCLC), while high levels of Angiopoietin-2 are strongly related to tumor angiogenesis, lymphangiogenesis, metastasis, and poor prognosis. Interestingly, the association of Angiopoietin-2 levels with the type of surgical approach makes Angiopoietin-2 a valuable factor in selecting the most suitable therapeutic strategy for lung cancer patients. The role of the Angiopoietin-1 and Angiopoietin-4 levels in NSCLC development requires further investigation. The present review focuses on the clinical impact of the Angiopoietin-1, Angiopoietin-2, and Angiopoietin-4 levels in patients diagnosed with NSCLC, emphasizing the interaction between them, and how they affect the development, progression, and metastasis of lung disease. Finally, it estimates the role of angiopoietins levels in the effective therapy of lung cancer patients. MDPI 2021-11-01 /pmc/articles/PMC8625006/ /pubmed/34833409 http://dx.doi.org/10.3390/medicina57111191 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tsakogiannis, Dimitris
Nikolakopoulou, Asimina
Zagouri, Flora
Stratakos, Grigorios
Syrigos, Konstantinos
Zografos, Eleni
Koulouris, Nikolaos
Bletsa, Garyfalia
Update Overview of the Role of Angiopoietins in Lung Cancer
title Update Overview of the Role of Angiopoietins in Lung Cancer
title_full Update Overview of the Role of Angiopoietins in Lung Cancer
title_fullStr Update Overview of the Role of Angiopoietins in Lung Cancer
title_full_unstemmed Update Overview of the Role of Angiopoietins in Lung Cancer
title_short Update Overview of the Role of Angiopoietins in Lung Cancer
title_sort update overview of the role of angiopoietins in lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625006/
https://www.ncbi.nlm.nih.gov/pubmed/34833409
http://dx.doi.org/10.3390/medicina57111191
work_keys_str_mv AT tsakogiannisdimitris updateoverviewoftheroleofangiopoietinsinlungcancer
AT nikolakopoulouasimina updateoverviewoftheroleofangiopoietinsinlungcancer
AT zagouriflora updateoverviewoftheroleofangiopoietinsinlungcancer
AT stratakosgrigorios updateoverviewoftheroleofangiopoietinsinlungcancer
AT syrigoskonstantinos updateoverviewoftheroleofangiopoietinsinlungcancer
AT zografoseleni updateoverviewoftheroleofangiopoietinsinlungcancer
AT koulourisnikolaos updateoverviewoftheroleofangiopoietinsinlungcancer
AT bletsagaryfalia updateoverviewoftheroleofangiopoietinsinlungcancer